Yiling Pharmaceutical responded to the doubt again, Yiling Pharmaceutical dropped to the limit and opened. Yiling Pharmaceutical responded to the doubt again, and Yiling Pharmaceutical dropped to the limit to open. In terms of news, Yiling Pharmaceutical previously stated that the company has never stated on any occasion
"WHO recommends Lianhua Qingwen."
Yiling Pharmaceutical responded to the doubts, and Yiling Pharmaceutical opened at the limit.
Yiling Pharmaceutical responded to the doubts, Yiling Pharmaceutical lowered the limit and opened 1. After lowering the limit on April 15, Yiling Pharmaceutical (002603) continued to lower the limit and opened on April 18. The current stock price is 32.39 yuan/share.
In terms of news, on April 17, Dr. Dingxiang published an article on his official Weibo, "Don't eat Lianhua Qingwen to prevent COVID-19." The article instantly went viral on the Internet.
Don’t take Lianhua Qingwen to prevent COVID-19. What is the future growth point of Wang Sicong’s Yiling Pharmaceutical?
At noon on April 14, 2022, Wang Sicong forwarded a message on Weibo questioning whether Lianhua Qingwen was recommended by the WHO, with the text saying, "The China Securities Regulatory Commission should strictly investigate Yiling Pharmaceuticals."
Although Wang Sicong took the initiative to delete the above remarks one hour after posting on Weibo, as public opinion fermented, on April 15, Yiling Pharmaceutical, the operating entity of Lianhua Qingwen, still hit the intraday limit, closing at 35.99
yuan/share, a drop of 10%, and the market value evaporated by 6.7 billion yuan that day.
In response to Wang Sicong’s doubts, on the afternoon of April 14, a staff member of the Securities Department of Yiling Pharmaceutical told Yinshi Finance, “As for the news posted on Weibo, please point out the specific problems and sources. Wang Sicong cannot be blamed.
Just ask questions at will." Perhaps because such a reply did not stop the stock price from falling, on April 16, Yiling Pharmaceutical officials once again stood up and told "China Entrepreneur": "The company has never stopped.
Say 'WHO recommends Lianhua Qingwen' on any occasion."
Yiling Pharmaceutical responded to the doubts, Yiling Pharmaceutical opened at the limit 2 On April 18, Yiling Pharmaceutical (002603) fell to the limit, with more than 100,000 orders closed, and it has been at the limit for two consecutive days.
In terms of news, Yiling Pharmaceutical previously stated that the company has never stated on any occasion that "WHO recommends Lianhua Qingwen."
According to the Securities Times, at 13:08 on April 14, Wang Sicong forwarded a message about Lianhua Qingwen Capsules on Weibo and said that regulatory authorities should strictly investigate Yiling Pharmaceuticals.
The comment quickly spread on the Internet.
In response to the comments on the Internet, Yiling Pharmaceutical quickly responded positively: "Regarding the news posted on Weibo, please point out the specific questions and sources, and we will answer the specific content. From clinical trials to specific experiments
From the data to the new coronavirus diagnosis and treatment plan, including indications and instructions, we have complete evidence and report disclosures. We cannot randomly raise questions because of the three words "Wang Sicong". Regarding some comments on the Internet,
Just listen, investors please be careful." About an hour later, Wang Sicong edited the Weibo post again, deleting the words "Regulatory authorities should strictly investigate Yiling Pharmaceuticals".
The Securities Times reported that since the outbreak of the new coronavirus, Lianhua Qingwen has shone brightly as a new coronavirus drug.
On April 14, the stock price of Yiling Pharmaceutical, the manufacturer of Lianhua Qingwen Capsules and an A-share listed company, also closed at the daily limit, with a turnover rate of 10.51% throughout the day and a turnover of 5.591 billion yuan.
Since the beginning of this year, Yiling Pharmaceutical’s stock price has increased by as much as 120%. Its latest market value is 54.1 billion yuan, and this year’s increase is still as high as 65%.
Market analysts said that Yiling Pharmaceutical, as a core listed company of proprietary Chinese medicines, is held by many institutions.
As of December 31, 2021, 65 fund institutions held 48.2679 million shares.
Among them, Industrial Global Fund’s four products*** hold 8.4447 million shares, Southern Fund’s nine products*** hold 6.5242 million shares of Yiling Pharmaceuticals, and Huaan Fund’s 10 products hold a total of 4.5109 million shares***
.
Looking at specific products, Xingquan Hexing, a two-year closed-operation mixed company managed by well-known fund manager Chen Yu, holds 2.3863 million shares, Huaan Ecological Preferred Mixed, managed by Chen Yuan, holds 1.8439 million shares, and Nanfang Baofeng Mixed, managed by Lin Lefeng and Sun Lumin,
Holds 100,000 shares.
As of press time on April 18, Yiling Pharmaceutical’s stock price was trading at 32.39 yuan, down 10.00%.
Yiling Pharmaceutical responded to the doubts, and Yiling Pharmaceutical opened at the limit 3. On April 18, Yiling Pharmaceutical opened at the limit, and fell by the limit for two consecutive days.
As of press time, Yiling Pharmaceutical's stock price was trading at 32.39 yuan per share, with a turnover rate of 0.77%, more than 280,000 orders sold, and a total market value of 54.1 billion yuan.
On the 14th, Wang Sicong forwarded a video questioning whether the World Health Organization had recommended Lianhua Qingwen Capsules.